<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974983</url>
  </required_header>
  <id_info>
    <org_study_id>Z-2017-0901-5</org_study_id>
    <nct_id>NCT04974983</nct_id>
  </id_info>
  <brief_title>Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma</brief_title>
  <official_title>Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent GBM: A Retrospective Patient Chart Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective non - interventional patient chart review will be utilizing real world&#xD;
      clinical data from patients treated for rGBM at the University Regensburg Medical center&#xD;
      either with or without bevacizumab. Only patients will be analyzed who were potentially&#xD;
      eligible for bevacizumab treatment. The study is designed to investigate the potential&#xD;
      effects of bevacizumab treatment on the functional status, symptom burden, neurological&#xD;
      deficits, time to tumor progression and overall survival between cohorts potentially eligible&#xD;
      for bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>15 months</time_frame>
    <description>Neurological deficits impacting functional independency</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">203</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Angiogenesis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Treatment without bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Treatment with bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation of neurological deficits</intervention_name>
    <description>Observation of neurological deficits</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recurrent glioblastoma either treated with or without bevacizumab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of recurrent glioblastoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Severe neurocognitive deficits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Regensburg</investigator_affiliation>
    <investigator_full_name>Martin Proescholdt</investigator_full_name>
    <investigator_title>Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

